Feasibility of a novel liquid fiducial marker for use in image guided radiotherapy of oesophageal cancer

Steen Riisgaard de Blanck*, Jonas Scherman-Rydhög, Mette Siemsen, Merete Christensen, Lene Baeksgaard, Rasmus Irming Jølck, Lena Specht, Thomas Lars Andresen, Gitte Fredberg Persson

*Corresponding author for this work

    Research output: Contribution to journalJournal articleResearchpeer-review

    84 Downloads (Pure)


    To evaluate the feasibility of a new liquid fiducial marker for use in image-guided radiotherapy for oesophageal cancer.

    Liquid fiducial markers were implanted in patients with metastatic or inoperable locally advanced oesophageal or gastro-oesophageal junction cancer receiving radiotherapy. Markers were implanted using a conventional gastroscope equipped with a 22 G Wang needle. Marker visibility was evaluated on fluoroscopy, CT, MRI and cone beam CT scans.

    Liquid markers (n = 16) were injected in four patients. No Grade 2 or worse adverse events were observed in relation to the implantation procedure, during treatment or in the follow-up period. 12/16 (75%) markers were available at the planning CT-scan and throughout the treatment- and follow-up period. The implanted markers were adequately visible in CT and cone beam CT but were difficult to distinguish in fluoroscopy and MRI without information from the corresponding CT image.

    Liquid fiducial marker placement in the oesophagus proved safe and clinically feasible.

    This paper presents the first clinical use of a new liquid fiducial marker in patients with oesophageal cancer and demonstrates that marker implantation using standard gastroscopic equipment and subsequent use in three-dimensional image-guided radiation therapy is safe and clinically feasible.
    Original languageEnglish
    Article number20180236
    JournalBritish Journal of Radiology
    Issue number1092
    Publication statusPublished - 2018


    Dive into the research topics of 'Feasibility of a novel liquid fiducial marker for use in image guided radiotherapy of oesophageal cancer'. Together they form a unique fingerprint.

    Cite this